Evidence map›Paper›PMID 35884446›Full record

ReviewCancers2022

The Significance of MicroRNAs in the Molecular Pathology of Brain Metastases.

Frantisek Siegl, Marek Vecera, Ivana Roskova, Martin Smrcka, Radim Jancalek, Tomas Kazda, Ondrej Slaby, Jiri Sana

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. MicroRNAs in Lung Cancer Brain Metastasis.International journal of molecular sciences · 2024
    Review
  4. Review
  5. The role of microRNAs in brain metastasis.Journal of neuro-oncology · 2024
    Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Frantisek SieglCentral European Institute of Technology, Masaryk University, 625 00 Brno, Czech Republic.
Marek VeceraCentral European Institute of Technology, Masaryk University, 625 00 Brno, Czech Republic.ORCID 0000-0001-7510-3694
Ivana RoskovaDepartment of Neurosurgery, University Hospital Brno and Faculty of Medicine of Masaryk University, 625 00 Brno, Czech Republic.
Martin SmrckaDepartment of Neurosurgery, University Hospital Brno and Faculty of Medicine of Masaryk University, 625 00 Brno, Czech Republic.ORCID 0000-0002-9191-8700
Radim JancalekDepartment of Neurosurgery, St. Annes University Hospital Brno and Faculty of Medicine of Masaryk University, 656 91 Brno, Czech Republic.ORCID 0000-0001-6834-6567
Tomas KazdaDepartment of Radiation Oncology, Masaryk Memorial Cancer Institute and Faculty of Medicine of Masaryk University, 656 53 Brno, Czech Republic.ORCID 0000-0001-7288-8975
Ondrej SlabyCentral European Institute of Technology, Masaryk University, 625 00 Brno, Czech Republic.
Jiri SanaCentral European Institute of Technology, Masaryk University, 625 00 Brno, Czech Republic.ORCID 0000-0003-1610-2215
Central European Institute of Technology · CZMasaryk University · CZ

Funding

Masaryk Memorial Cancer Institute 00209805Ministry of Health Czech Republic NV18-03-00398University Hospital Brno 65269705
6 · The paper itself

Abstract

Brain metastases are the most frequent intracranial tumors in adults and the cause of death in almost one-fourth of cases. The incidence of brain metastases is steadily increasing. The main reason for this increase could be the introduction of new and more efficient therapeutic strategies that lead to longer survival but, at the same time, cause a higher risk of brain parenchyma infiltration. In addition, the advances in imaging methodology, which provide earlier identification of brain metastases, may also be a reason for the higher recorded number of patients with these tumors. Metastasis is a complex biological process that is still largely unexplored, influenced by many factors and involving many molecules. A deeper understanding of the process will allow the discovery of more effective diagnostic and therapeutic approaches that could improve the quality and length of patient survival. Recent studies have shown that microRNAs (miRNAs) are essential molecules that are involved in specific steps of the metastatic cascade. MiRNAs are endogenously expressed small non-coding RNAs that act as post-transcriptional regulators of gene expression and thus regulate most cellular processes. The dysregulation of these molecules has been implicated in many cancers, including brain metastases. Therefore, miRNAs represent promising diagnostic molecules and therapeutic targets in brain metastases. This review summarizes the current knowledge on the importance of miRNAs in brain metastasis, focusing on their involvement in the metastatic cascade and their potential clinical implications.

Indexed as

biomarkersbrain metastasesmetastatic cascademicroRNA

Identifiers

PMID35884446
PMCPMC9322877
OpenAlexW4285093953

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.